ApoGen Biotechnologies, Inc.

📍 Seattle, United States🗓 Founded 2014👥 1 employees💰 Last funded Aug 2018
Pharmaceutical Manufacturing🌐 apogenbiotech.com
Website LinkedIn
As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant…nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival. ApoGen Biotechnologies is developing novel oncology therapeutics targeting the key drivers of mutation and cancer genomic evolution to overcome drug resistance. (www.apogenbiotech.com)
4
Total investors
1
Early stage
3
Mid stage
0
Late stage
2014
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Netherlands
2
United States
1
Investor activity2013–2018 · investors recorded per year
201312017120182
Recent (last 2y)Earlier
Frequently asked questions
Who invested in ApoGen Biotechnologies, Inc.?
ApoGen Biotechnologies, Inc. has 4 investors on record on gritt.io, including 1 early-stage backers, 3 mid-stage.
When did ApoGen Biotechnologies, Inc. last raise funding?
The most recent investment in ApoGen Biotechnologies, Inc. recorded on gritt.io was in August 2018.
When was ApoGen Biotechnologies, Inc. founded?
ApoGen Biotechnologies, Inc. was founded in 2014.
What industry is ApoGen Biotechnologies, Inc. in?
ApoGen Biotechnologies, Inc. operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is ApoGen Biotechnologies, Inc. based?
ApoGen Biotechnologies, Inc. is headquartered in Seattle, United States.